Abstract:Botulinum neurotoxins (BoNTs) are a family of bacterial toxins with seven major serotypes (BoNT/A-G). The ability of these toxins to target and bind to motor nerve terminals is a key factor determining their potency and efficacy. Among these toxins, BoNT/B is one of the two types approved for medical and cosmetic uses. Besides binding to well-established receptors, an extended loop in the C-terminal receptor-binding domain (HC) of BoNT/B (HC/B) has been proposed to also contribute to toxin binding to neurons by interacting with lipid membranes (termed lipid-binding loop [LBL]). Analogous loops exist in the HCs of BoNT/C, D, G, and a chimeric toxin DC. However, it has been challenging to detect and characterize binding of LBLs to lipid membranes. Here, using the nanodisc system and biolayer interferometry assays, we find that HC/DC, C, and G, but not HC/B and HC/D, are capable of binding to receptor-free lipids directly, with HC/DC having the highest level of binding. Mutagenesis studies demonstrate the critical role of consecutive aromatic residues at the tip of the LBL for binding of HC/DC to lipid membranes. Taking advantage of this insight, we then create a "gain-of-function" mutant HC/B by replacing two nonaromatic residues at the tip of its LBL with tryptophan. Cocrystallization studies confirm that these two tryptophan residues do not alter the structure of HC/B or the interactions with its receptors. Such a mutated HC/B gains the ability to bind receptor-free lipid membranes and shows enhanced binding to cultured neurons. Finally, full-length BoNT/B containing two tryptophan mutations in its LBL, together with two additional mutations (E1191M/S1199Y) that increase binding to human receptors, is produced and evaluated in mice in vivo using Digit Abduction Score assays. This mutant toxin shows enhanced efficacy in paralyzing local muscles at the injection site and lower systemic diffusion, thus extending both safety range and duration of paralysis compared with the control BoNT/B. These findings establish a mechanistic understanding of LBL-lipid interactions and create a modified BoNT/B with improved therapeutic efficacy.

Characterization of a Membrane Binding Loop Leads to Engineering Botulinum Neurotoxin B with Improved Therapeutic Efficacy.

Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models.

Engineered Botulinum Neurotoxin B with Improved Efficacy for Targeting Human Receptors.

Probing the structure and function of the protease domain of botulinum neurotoxins using single-domain antibodies

Synaptotagmin Binding to Botulinum Neurotoxins

Covalent modifiers of Botulinum neurotoxin counteract toxin persistence.

Activity of Botulinum Neurotoxin X and Its Structure when Shielded by a Non-Toxic Non-Hemagglutinin Protein

Biological and Immunological Characterization of a Functional L-HN Derivative of Botulinum Neurotoxin Serotype F

Structural characterisation of the catalytic domain of botulinum neurotoxin X - high activity and unique substrate specificity

Identification and characterization of a novel botulinum neurotoxin

Cell-Penetrating Botulinum Neurotoxin Type A With Improved Cellular Uptake and Therapeutic Index

Botulinum neurotoxins: Future innovations

Structure and activity of botulinum neurotoxin X.

Structural Basis for the Unique Ganglioside and Cell Membrane Recognition Mechanism of Botulinum Neurotoxin DC

Isolation and characterization of Hc-targeting chimeric heavy chain antibodies neutralizing botulinum neurotoxin type B

Crystal structures of botulinum neurotoxin DC in complex with its protein receptors synaptotagmin I and II.

Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2

Crystal Structure of the Botulinum Neurotoxin Type G Binding Domain: Insight into Cell Surface Binding

Discovery of a Potent Botulinum Neurotoxin A Inhibitor ZM299 with Effective Protections in Botulism Mice

Progress in study on the mechanism of botulinum neurotoxin actions

Resolution of Two Steps in Botulinum Neurotoxin Serotype A1 Light Chain Localization to the Intracellular Plasma Membrane